Colorectal cancer is a type of cancer that begins in the large intestine (colon). The cancer can also be called colon cancer or rectal cancer, depending on where they start. Colorectal cancer screening is important because when found early, colorectal cancer is highly treatable. Early stages of colorectal cancer usually present no symptoms. Regular screenings may reduce the risk for death and complications caused by colorectal cancer. Screening help find cancer at an early stage, before symptoms appear. If the cancer is diagnosed at a localized stage, the survival rate is 90%. If the cancer spread to surrounding tissues or organs and/or the regional lymph nodes, the 5-year survival rate is 73%. If the cancer has spread to distant parts of the body, the 5-year survival rate is 17%.
Market Dynamics:
Increasing prevalence of colorectal cancer, increasing cancer prevention initiatives, and rise in awareness among people about colorectal cancer screening are some major factors expected to aid in the growth of the global colorectal cancer screening market during the forecast period. For instance, colorectal cancer can be a deadly disease, but without proactive screenings, it’s one that often goes unnoticed or undiagnosed in its early stages. Screenings are the No. 1 way to detect colorectal cancers and in most cases are covered 100% by most insurance plans. The US government, in 2021, declared March as the National Colorectal Cancer Awareness Month to increase awareness on colorectal cancer management, bringing attention to colorectal cancer, the third most commonly diagnosed cancer in the U.S.
Key features of the study:
- This report provides in-depth analysis of the global colorectal cancer screening market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global colorectal cancer screening market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Siemens Healthineers, Quidel Corporation, Novigenix SA, Hemosure Inc., Exact Sciences Corp., Epigenomics Inc., Olympus Corporation, and Clinical Genomics Technologies Pty Ltd., among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global colorectal cancer screening market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global colorectal cancer screening market.
Detailed Segmentation:
- Global Colorectal Cancer Screening Market, By Screening Tests:
-
- Stool-based Tests
- Colonoscopy
- CT Colonography (Virtual Colonoscopy)
- Flexible Sigmoidoscopy
- Other Screening Tests
- Global Colorectal Cancer Screening Market, By End User:
-
- Hospitals Independent Diagnostic Labs
- Other End Users
- Global Colorectal Cancer Screening Market, By Geography:
-
- North America
- South America
- Europe
- Asia-Pacific
- Middle East & Africa